TYKERB© (lapatinib ditosylate monohydrate) – Comparative data have shown that Lapatinib based regimens are less effective than Herceptin© (trastuzumab) based regimens in certain settings

GlaxoSmithKline would like to notify healthcare professionals of important study results concerning the efficacy of TYKERB©. Two recent trials have shown statistically significant superior efficacy of trastuzumab in combination with chemotherapy as compared to lapatinib in combination with chemotherapy. This effect was observed in patients with HER2 positive metastatic breast cancer regardless of whether they had previously received trastuzumab; however, the effect was more pronounced in the patients who had no prior exposure to trastuzumab. Healthcare professionals are reminded that TYKERB© in combination with capecitabine is to be used in patients with advanced or metastatic disease with progression following prior therapy which must have included trastuzumab in the metastatic setting.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

24 Feb 2021

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.